SCHEMBL1768874

SCHEMBL1768874

CN(C)c1ccccc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 1/20 0.46
CYP1A2 P05177 3/20 0.42
TSHR P16473 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
CYP3A4 P08684 2/20 0.42
MAPK1 P28482 2/20 0.42
ALOX15 P16050 1/20 0.42
HIF1A Q16665 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CLK4 Q9HAZ1 3/20 0.40
ALDH1A1 P00352 3/20 0.40
GAA P10253 3/20 0.40
MAPT P10636 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 1/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ESR1 P03372 1/20 0.40
PDK2 Q15119 1/20 0.40
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30454780 1.00 ACP1 (0.46) ACP1CYP1A2TSHRTDP1CYP3A4
SCHEMBL6735075 0.82 MAPT (0.38) ACP1CYP1A2TSHRTDP1CYP3A4
SCHEMBL22651898 0.80 RORC (0.38) ACP1CYP1A2TSHRTDP1CYP3A4
SCHEMBL8979233 0.79 ALDH1A1 (0.38) ACP1CYP1A2TSHRTDP1CYP3A4
SCHEMBL5539229 0.79 ESR1 (0.39) ACP1CYP1A2TSHRTDP1CYP3A4
SCHEMBL17479870 0.79 HDAC6 (0.45) ACP1CYP1A2TSHRTDP1CYP3A4
SCHEMBL28122138 0.79 ESR1 (0.39) ACP1CYP1A2TSHRTDP1CYP3A4
SCHEMBL1201242 0.78 ALDH1A1 (0.46) ACP1TSHRTDP1MAPK1CLK4
SCHEMBL29987688 0.78 ALDH1A1 (0.46) ACP1TSHRTDP1MAPK1CLK4
SCHEMBL2093130 0.77 ESR1 (0.38) ACP1CYP1A2TSHRTDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717457-A1 PROCESS FOR PREPARATION OF ENZALUTAMIDE USING NOVEL INTERMEDIATE Aarti Industries Limited (IN) 2020-10-07 EP claimed
US-20250369146-A1 AMMONIUM SALT COMPOUND, ADDITIVE FOR ELECTROLYTIC COPPER PLATING, ELECTROLYTIC COPPER PLATING SOLUTION COMPOSITION AND ELECTROLYTIC COPPER PLATING METHOD SAMSUNG ELECTRONICS CO LTD (KR) 2025-12-04 US disclosed
EP-4139308-B1 PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES COMMISSARIAT ENERGIE ATOMIQUE (FR) 2024-07-17 EP disclosed
WO-2023188949-A1 SECONDARY BATTERY ELECTROLYTE AND SECONDARY BATTERY 株式会社村田製作所 2023-10-05 WO disclosed
US-20230284516-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-09-07 US disclosed
US-20230200211-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-06-22 US disclosed
EP-3717457-B1 PROCESS FOR PREPARATION OF ENZALUTAMIDE USING NOVEL INTERMEDIATE AARTI INDUSTRIES LTD (IN) 2023-06-21 EP disclosed
US-20220396596-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2022-12-15 US disclosed
US-20220223790-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND POLYCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2022-07-14 US disclosed
WO-2021223736-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON PHARMACEUTICALS, LTD. (CN) 2021-11-11 WO disclosed
US-7173032-B2 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-02-06 US disclosed
US-7173032-B2 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-02-06 US disclosed
EP-0144206-B1 PROCESS FOR SYNTHESISING SQUARAINE COMPOSITIONS XEROX CORPORATION (US) 1989-04-19 EP disclosed
EP-0146301-B1 PROCESS FOR SYNTHESIZING SQUARAINE COMPOSITIONS XEROX CORPORATION (US) 1988-07-13 EP disclosed
US-4606986-A Electrophotographic elements containing unsymmetrical squaraines XEROX CORPORATION (US) 1986-08-19 US disclosed
EP-0146301-A1 Process for synthesizing squaraine compositions XEROX CORPORATION (US) 1985-06-26 EP disclosed
EP-0144206-A2 Process for synthesising squaraine compositions XEROX CORPORATION (US) 1985-06-12 EP disclosed
US-4523035-A BLUE AND GREEN PIGMENTS XEROX CORPORATION (US) 1985-06-11 US disclosed
US-4521621-A Novel squarine systems XEROX CORPORATION (US) 1985-06-04 US disclosed
US-4096185-A P-CHLOROBENZOTRIFLUORIDE, AMMONIA, COPPER COMPOUND CATALYST E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220396596-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD2, OCIAD1, DRD3 ACP1 3717/4885CYP1A2 817/4885TSHR 2845/4885
US-20230284516-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OXER1, LBR, C1R ACP1 3099/4885CYP1A2 902/4885TSHR 190/4885
US-20220223790-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND POLYCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE SLCO2A1, SLCO4C1, TMEM109 ACP1 3138/4885CYP1A2 1059/4885TSHR 4512/4885
US-20230200211-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD2, OPRM1, OCIAD1 ACP1 3005/4885CYP1A2 432/4885TSHR 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.